Clinical Trial Update: A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MEK162 to physician's choice chemotherapy in low-grade serous ovarian/fallopian tube/peritoneal cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Fallopian Tube Cancer
• Low-grade Serous Ovarian Cancer
• Low-grade Serous Peritoneal Cancer

Drugs mentioned

• MEK162 (binimetinib)

Snippet

Sponsor: Pfizer | Conditions: Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer | Phase 3 | Status: TERMINATED | Results posted: 2021-03-30